SPL-334 is an inhibitor of S-Nitrosoglutathione reductase (GSNOR), the enzyme responsible for regulating cellular concentrations of S-Nitrosoglutathione (GSNO), which plays a critical role in nitric oxide signaling in the respiratory tract. In a mouse model of allergic airway inflammation, SPL-334 reduced airway hyperreactivity, and in a bleomycin injury model of interstitial lung disease, SPL-334 reduced lung inflammation and fibrosis. Studies for treatment of asthma, idiopathic pulmonary fibrosis (IPF), and inflammation are ongoing.
SPL-334 is an inhibitor of S-Nitrosoglutathione reductase (GSNOR).
The Journal of pharmacology and experimental therapeutics, 355(1), 13-22 (2015-07-26)
Interstitial lung disease (ILD) characterized by pulmonary fibrosis and inflammation poses a substantial biomedical challenge due to often negative disease outcomes combined with the need to develop better, more effective therapies. We assessed the in vivo effect of administration of
Allergic asthma is characterized by Th2 type inflammation, leading to airway hyperresponsivenes, mucus hypersecretion and tissue remodeling. S-Nitrosoglutathione reductase (GSNOR) is an alcohol dehydrogenase involved in the regulation of intracellular levels of S-nitrosothiols. GSNOR activity has been shown to be
The Journal of biological chemistry, 284(36), 24354-24362 (2009-07-15)
S-Nitrosoglutathione reductase (GSNOR) is an alcohol dehydrogenase involved in the regulation of S-nitrosothiols (SNOs) in vivo. Knock-out studies in mice have shown that GSNOR regulates the smooth muscle tone in airways and the function of beta-adrenergic receptors in lungs and
Preguntas
Revisiones
★★★★★ Sin puntuación
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
